Key points are not available for this paper at this time.
Abstract Chikungunya virus (CHIKV), transmitted by mosquitoes, poses a significant global health threat. Presently, no effective treatment options are available to reduce the disease burden. The lack of approved therapeutics against CHIKV and the complex spectrum of chronic musculoskeletal and neurological manifestations raise significant concerns, and repurposing drugs could offer swift avenues in the development of effective treatment strategies. RNA capping is a crucial step meditated by non-structural protein 1 (nsP1) in CHIKV replication. In this study, FDA-approved antivirals targeting CHIKV nsP1 methyltransferase (MTase) have been identified by structure-based virtual screening. Berbamine Hydrochloride (BH), ABT199/Venetoclax (ABT), and Ponatinib (PT) were the top hits, which exhibited robust binding energies. Tryptophan fluorescence spectroscopy-based assay confirmed binding of BH-, ABT-, and PT to purified nsP1 with K D values ∼5.45 μM, ∼161.3 μM, and ∼3.83μM, respectively. A dose-dependent decrease in CHIKV nsP1 MTase activity was observed in a capillary electrophoresis-based assay. Treatment with BH, ABT, and PT lead to a dose-dependent reduction in the virus titer with IC 50 1.25 μM, respectively. These results underscore the efficacy and promise of repurposing drugs as rapid and effective antiviral therapeutics against CHIKV. Highlights Berbamine Hydrochloride (BH), ABT199/Venetoclax (ABT), and Ponatinib (PT) identified as inhibitors of Chikungunya virus (CHIKV) nsP1 Molecules BH, ABT and PT make moelcular interactions with nsP1: K D values ∼5.45, ∼161.3, and ∼3.83 in μM, respectively and effectively inhibit methyltransferase activity. BH, ABT, and PT exhibited potent antiviral activity against CHIKV in cell-based assays, with IC 50 1.25 μM respectively demonstrating broad spectrum antiviral efficacy. Graphical Abstract
Bhutkar et al. (2024) studied this question.